PARSIPPANY, NJ: Watson Pharmaceuticals is preparing for an awareness effort to alert stakeholders about its rebranding as Actavis. The multi-year rebranding campaign will kick off at the beginning of next year.
The name change follows Watson's acquisition of the Actavis Group for $5.4 billion at the end of last month. The merger resulted in Watson adding four staff members to its communications team and the departure of Frank Staud, Actavis' EVP of communications, according to Charlie Mayr, Watson's CCO. Mayr will ...